Pulmonary Hypertension and Eisenmenger Physiology

  • Jonathan Kochav
Part of the In Clinical Practice book series (ICP)


  • It is estimated that 10% of patients with repaired and up to 30% of patients with unrepaired congenital heart disease with left-to-right shunting also have pulmonary arterial hypertension. This chapter focuses on the pathophysiology, diagnosis, and management of patients who develop pulmonary hypertension as well as those who progress to Eisenemger physiology with reversal of shunt flow.


  1. 1.
    Engelfriet PM, Duffels MG, Moller T, et al. Pulmonary arterial hypertension in adults born with a heart septal defect: the Euro Heart Survey on adult congenital heart disease. Heart. 2007;93:682–7.CrossRefGoogle Scholar
  2. 2.
    Eisenmenger V. Die angeborenen Defekte der Kammerscheidewände des Herzens. Zeitschr Klin Med. 1897;32:1–28.Google Scholar
  3. 3.
    Wood P. The Eisenmenger syndrome or pulmonary hypertension with reversed central shunt. Br Med J. 1958;2:755–62.CrossRefGoogle Scholar
  4. 4.
    Warnes CA, Williams RG, Bashore TM, et al. ACC/AHA 2008 guidelines for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines (writing committee to develop guidelines on the management of adults with congenital heart disease). Circulation. 2008;118:e714–833.PubMedGoogle Scholar
  5. 5.
    Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013;62:D34–41.CrossRefGoogle Scholar
  6. 6.
    Manes A, Palazzini M, Leci E, Bacchi Reggiani ML, Branzi A, Galie N. Current era survival of patients with pulmonary arterial hypertension associated with congenital heart disease: a comparison between clinical subgroups. Eur Heart J. 2014;35:716–24.CrossRefGoogle Scholar
  7. 7.
    Duffels MG, Engelfriet PM, Berger RM, et al. Pulmonary arterial hypertension in congenital heart disease: an epidemiologic perspective from a Dutch registry. Int J Cardiol. 2007;120:198–204.CrossRefGoogle Scholar
  8. 8.
    Moceri P, Kempny A, Liodakis E, et al. Physiological differences between various types of Eisenmenger syndrome and relation to outcome. Int J Cardiol. 2015;179:455–60.CrossRefGoogle Scholar
  9. 9.
    Alonso-Gonzalez R, Lopez-Guarch CJ, Subirana-Domenech MT, et al. Pulmonary hypertension and congenital heart disease: an insight from the REHAP National Registry. Int J Cardiol. 2015;184:717–23.CrossRefGoogle Scholar
  10. 10.
    Vongpatanasin W, Brickner ME, Hillis LD, Lange RA. The Eisenmenger syndrome in adults. Ann Intern Med. 1998;128:745–55.CrossRefGoogle Scholar
  11. 11.
    Tuder RM, Cool CD, Yeager M, Taraseviciene-Stewart L, Bull TM, Voelkel NF. The pathobiology of pulmonary hypertension. Endothelium Clin Chest Med. 2001;22:405–18.CrossRefGoogle Scholar
  12. 12.
    Post MC, Janssens S, Van de Werf F, Budts W. Responsiveness to inhaled nitric oxide is a predictor for mid-term survival in adult patients with congenital heart defects and pulmonary arterial hypertension. Eur Heart J. 2004;25:1651–6.CrossRefGoogle Scholar
  13. 13.
    Diller GP, Gatzoulis MA. Pulmonary vascular disease in adults with congenital heart disease. Circulation. 2007;115:1039–50.CrossRefGoogle Scholar
  14. 14.
    Hopkins WE, Ochoa LL, Richardson GW, Trulock EP. Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome.J Heart Lung Transplant. 1996;15:100–5.PubMedGoogle Scholar
  15. 15.
    Cantor WJ, Harrison DA, Moussadji JS, et al. Determinants of survival and length of survival in adults with Eisenmenger syndrome. Am J Cardiol. 1999;84:677–81.CrossRefGoogle Scholar
  16. 16.
    Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Rev Esp Cardiol (Engl Ed). 2016;69:177.CrossRefGoogle Scholar
  17. 17.
    Roth TS, Aboulhosn JA. Pulmonary hypertension and congenital heart disease. Cardiol Clin. 2016;34:391–400.CrossRefGoogle Scholar
  18. 18.
    Frost AE, Quinones MA, Zoghbi WA, Noon GP. Reversal of pulmonary hypertension and subsequent repair of atrial septal defect after treatment with continuous intravenous epoprostenol. J Heart Lung Transplant. 2005;24:501–3.CrossRefGoogle Scholar
  19. 19.
    Schwerzmann M, Zafar M, McLaughlin PR, Chamberlain DW, Webb G, Granton J. Atrial septal defect closure in a patient with “irreversible” pulmonary hypertensive arteriopathy. Int J Cardiol. 2006;110:104–7.CrossRefGoogle Scholar
  20. 20.
    Stoica SC, McNeil KD, Perreas K, et al. Heart-lung transplantation for Eisenmenger syndrome: early and long-term results. Ann Thorac Surg. 2001;72:1887–91.CrossRefGoogle Scholar
  21. 21.
    Dimopoulos K, Inuzuka R, Goletto S, et al. Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension. Circulation. 2010;121:20–5.CrossRefGoogle Scholar
  22. 22.
    Zhang ZN, Jiang X, Zhang R, et al. Oral sildenafil treatment for Eisenmenger syndrome: a prospective, open-label, multicentre study. Heart. 2011;97:1876–81.CrossRefGoogle Scholar
  23. 23.
    Sun YJ, Yang T, Zeng WJ, et al. Impact of sildenafil on survival of patients with Eisenmenger syndrome. J Clin Pharmacol. 2013;53:611–8.CrossRefGoogle Scholar
  24. 24.
    Mukhopadhyay S, Sharma M, Ramakrishnan S, et al. Phosphodiesterase-5 inhibitor in Eisenmenger syndrome: a preliminary observational study. Circulation. 2006;114:1807–10.CrossRefGoogle Scholar
  25. 25.
    Mukhopadhyay S, Nathani S, Yusuf J, Shrimal D, Tyagi S. Clinical efficacy of phosphodiesterase-5 inhibitor tadalafil in Eisenmenger syndrome—a randomized, placebo-controlled, double-blind crossover study. Congenit Heart Dis. 2011;6:424–31.CrossRefGoogle Scholar
  26. 26.
    Galie N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation. 2006;114:48–54.CrossRefGoogle Scholar
  27. 27.
    Gatzoulis MA, Beghetti M, Galie N, et al. Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: results of the BREATHE-5 open-label extension study. Int J Cardiol. 2008;127:27–32.CrossRefGoogle Scholar
  28. 28.
    Zuckerman WA, Leaderer D, Rowan CA, Mituniewicz JD, Rosenzweig EB. Ambrisentan for pulmonary arterial hypertension due to congenital heart disease. Am J Cardiol. 2011;107:1381–5.CrossRefGoogle Scholar
  29. 29.
    Rosenkranz S, Ghofrani HA, Beghetti M, et al. Riociguat for pulmonary arterial hypertension associated with congenital heart disease. Heart. 2015;101:1792–9.CrossRefGoogle Scholar
  30. 30.
    Sitbon O, Channick R, Chin KM, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373:2522–33.CrossRefGoogle Scholar
  31. 31.
    Cha KS, Cho KI, Seo JS, et al. Effects of inhaled iloprost on exercise capacity, quality of life, and cardiac function in patients with pulmonary arterial hypertension secondary to congenital heart disease (the Eisenmenger syndrome) (from the EIGER study). Am J Cardiol. 2013;112:1834–9.CrossRefGoogle Scholar
  32. 32.
    Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation. 1999;99:1858–65.CrossRefGoogle Scholar
  33. 33.
    D'Alto M, Romeo E, Argiento P, et al. Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology. Int J Cardiol. 2012;155:378–82.CrossRefGoogle Scholar
  34. 34.
    Iversen K, Jensen AS, Jensen TV, Vejlstrup NG, Sondergaard L. Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial. Eur Heart J. 2010;31:1124–31.CrossRefGoogle Scholar
  35. 35.
    Broberg CS, Ujita M, Prasad S, et al. Pulmonary arterial thrombosis in Eisenmenger syndrome is associated with biventricular dysfunction and decreased pulmonary flow velocity. J Am Coll Cardiol. 2007;50:634–42.CrossRefGoogle Scholar
  36. 36.
    Sandoval J, Aguirre JS, Pulido T, et al. Nocturnal oxygen therapy in patients with the Eisenmenger syndrome. Am J Respir Crit Care Med. 2001;164:1682–7.CrossRefGoogle Scholar
  37. 37.
    Ammash N, Warnes CA. Cerebrovascular events in adult patients with cyanotic congenital heart disease. J Am Coll Cardiol. 1996;28:768–72.CrossRefGoogle Scholar
  38. 38.
    Daliento L, Somerville J, Presbitero P, et al. Eisenmenger syndrome. Factors relating to deterioration and death. Eur Heart J. 1998;19:1845–55.CrossRefGoogle Scholar
  39. 39.
    Oya H, Nagaya N, Satoh T, et al. Haemodynamic correlates and prognostic significance of serum uric acid in adult patients with Eisenmenger syndrome. Heart. 2000;84:53–8.CrossRefGoogle Scholar
  40. 40.
    Weiss BM, Zemp L, Seifert B, Hess OM. Outcome of pulmonary vascular disease in pregnancy: a systematic overview from 1978 through 1996. J Am Coll Cardiol. 1998;31:1650–7.CrossRefGoogle Scholar
  41. 41.
    Canobbio MM, Warnes CA, Aboulhosn J, et al. Management of pregnancy in patients with complex congenital heart disease: a scientific statement for healthcare professionals from the American Heart Association. Circulation. 2017;135(8):e50–87.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Jonathan Kochav
    • 1
  1. 1.Massachusetts General HospitalBostonUSA

Personalised recommendations